Invivyd, Inc. Files 8-K
Ticker: IVVD · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, corporate-reporting
TL;DR
Invivyd filed a routine 8-K on Jan 10, 2025. No major news.
AI Summary
Invivyd, Inc. filed an 8-K on January 10, 2025, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incorporated in Delaware and headquartered in Waltham, MA. This filing does not appear to contain specific financial transaction details or significant business updates beyond routine reporting.
Why It Matters
This 8-K filing indicates routine corporate reporting by Invivyd, Inc. to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing appears to be a standard, routine disclosure without any immediately apparent negative or positive material events.
Key Players & Entities
- Invivyd, Inc. (company) — Registrant
- Adagio Therapeutics, Inc. (company) — Former Name
- January 10, 2025 (date) — Filing Date
- Waltham, MA (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Invivyd, Inc.?
The 8-K filing on January 10, 2025, is for reporting 'Other Events' and 'Financial Statements and Exhibits' as per SEC regulations.
When was Invivyd, Inc. formerly known as?
Invivyd, Inc. was formerly known as Adagio Therapeutics, Inc., with a name change date of November 12, 2020.
Where are Invivyd, Inc.'s principal executive offices located?
Invivyd, Inc.'s principal executive offices are located at 1601 Trapelo Road, Suite 178, Waltham, MA 02451.
What is the IRS Employer Identification Number for Invivyd, Inc.?
The IRS Employer Identification Number for Invivyd, Inc. is 85-1403134.
What is the Commission File Number for Invivyd, Inc.?
The Commission File Number for Invivyd, Inc. is 001-40703.
Filing Stats: 432 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2025-01-10 07:08:18
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar
Filing Documents
- ivvd-20250110.htm (8-K) — 52KB
- ivvd-ex99_1.htm (EX-99.1) — 36KB
- img59752938_0.jpg (GRAPHIC) — 84KB
- 0000950170-25-003781.txt ( ) — 328KB
- ivvd-20250110.xsd (EX-101.SCH) — 27KB
- ivvd-20250110_htm.xml (XML) — 5KB
01
Item 8.01. Other Events. On January 10, 2025, Invivyd, Inc. issued a press release entitled "Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) against dominant SARS-CoV-2 Variant XEC." A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated January 10, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: January 10, 2025 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary